{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:25:47Z","timestamp":1794885947305,"version":"4.9.1"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:p>\n                    Programmed death-ligand 1 (PD-L1) is a crucial negative costimulatory molecule expressed on both tumor and immune cells. It binds to programmed death-1, facilitating tumor escape. Tumor-infiltrating immune cells play a vital role in this process. However, the clinical relationship between PD-L1 expression and tumor-infiltrating immune cells remains uncertain. Immunohistochemistry (IHC) was utilized to assess PD-L1 expression and TIIC markers (CD3, CD4, CD8, CD19, CD31, CD68, CD11c, CD56, and \u03b1-smooth muscle actin) in gastric adenocarcinoma tissues from 268 patients. The aim was to explore the prognostic significance of PD-L1 and the infiltration of different immune cell types. The study analyzed overall survival and the correlations between PD-L1 expression, immune cell infiltration, and clinicopathological characteristics. Among the 268 patients, 52 (19.40%) exhibited high PD-L1 expression on tumor cells (TPD-L1), while 167 (62.31%) displayed high PD-L1 expression on immune cells (IPD-L1). Patients with high IPD-L1 expression showed improved survival compared to those with low IPD-L1 expression (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.028). High TPD-L1 expression associated with various clinicopathological features, such as larger tumor size, poorer differentiation, deeper invasion depth, and higher tumor stage. Conversely, patients with high IPD-L1 expression exhibited shallower tumor invasion and lower mortality rates. Univariate analysis indicated that superficial tumor infiltration, absence of lymph node and distant metastasis, low tumor stage, high IPD-L1 expression, and elevated CD8 and CD19 expression were associated with a reduced risk of tumor progression. Multivariate analysis revealed that patients with high IPD-L1 and CD8 expression or high TPD-L1 and low CD31 expression experienced significantly better overall survival than patients with other combinations. The findings indicate that patients with high PD-L1 expression in immune cells have a substantially improved prognosis. Additionally, the combination of PD-L1 with CD8 or CD31 expression status can serve as an indicator of prognosis in patients with gastric adenocarcinoma.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000036323","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T22:02:27Z","timestamp":1701468147000},"page":"e36323","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment"],"prefix":"10.1097","volume":"102","author":[{"given":"Qiuying","family":"Quan","sequence":"first","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingchuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Children\u2019s Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiju","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Changshu Hospital of Affiliated to Nanjing University of Chinese Medicine, Changshu, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Ding","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-8112","authenticated-orcid":false,"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"},{"name":"Jiangsu Key Laboratory of Clinical Immunology, Soochow University, Suzhou, Jiangsu, China"},{"name":"Jiangsu Key Laboratory of Gastrointestinal Tumor Immunology, Suzhou, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer.","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 22022, NCCN clinical practice guidelines in oncology.","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2217\/fon-2021-0084","article-title":"Current and potential biomarkers in gastric cancer: a critical review of the literature.","volume":"17","author":"De Mello","year":"2021","journal-title":"Future Oncol"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jncc.2020.12.001","article-title":"Cancer incidence and mortality in China, 2015.","volume":"1","author":"Zhang","year":"2021","journal-title":"J Natl Cancer Center"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome.","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"e29304","DOI":"10.1097\/MD.0000000000029304","article-title":"The current management and biomarkers of immunotherapy in advanced gastric cancer.","volume":"101","author":"Chang","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-022-00297-8","article-title":"Current insight into the regulation of PD-L1 in cancer.","volume":"11","author":"Liu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"120827","DOI":"10.1016\/j.lfs.2022.120827","article-title":"Targeting PD-1\/PD-L1 axis as new horizon for ovarian cancer therapy.","volume":"306","author":"Khatoon","year":"2022","journal-title":"Life Sci"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00262-021-03107-y","article-title":"The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.","volume":"71","author":"Zamora","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1093\/oncolo\/oyac051","article-title":"Multicenter real-world study on effectiveness and early discontinuation predictors in patients with non-small cell lung cancer receiving nivolumab.","volume":"27","author":"Pasello","year":"2022","journal-title":"Oncologist"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.euf.2020.09.010","article-title":"Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences.","volume":"7","author":"Tural","year":"2021","journal-title":"Eur Urol Focus"},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"e004440","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.","volume":"10","author":"Lopez de Rodas","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1038\/s41598-021-85966-0","article-title":"PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.","volume":"11","author":"Bekos","year":"2021","journal-title":"Sci Rep"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"768","DOI":"10.20892\/j.issn.2095-3941.2020.0121","article-title":"Molecular heterogeneity of anti-PD-1\/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.","volume":"17","author":"Jin","year":"2020","journal-title":"Cancer Biol Med"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer.","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"R17-20260811","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"R18-20260811","doi-asserted-by":"crossref","first-page":"1073274821997430","DOI":"10.1177\/1073274821997430","article-title":"The anti-PD-1\/PD-L1 immunotherapy for gastric esophageal cancer: a systematic review and meta-analysis and literature review.","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Control"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/ijms19051272","article-title":"Contribution of tumor endothelial cells in cancer progression.","volume":"19","author":"Hida","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R21-20260811","first-page":"1555","article-title":"Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression.","volume":"54","author":"Huang","year":"2019","journal-title":"Int J Oncol"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts.","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"e14663","DOI":"10.1097\/MD.0000000000014663","article-title":"Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.","volume":"98","author":"Guo","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"1758835920965840","DOI":"10.1177\/1758835920965840","article-title":"PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China.","volume":"12","author":"Li","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"110504","DOI":"10.1016\/j.biopha.2020.110504","article-title":"Research progress of PD-1\/PD-L1 immunotherapy in gastrointestinal tumors.","volume":"129","author":"Sun","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"2496582","DOI":"10.1155\/2020\/2496582","article-title":"Profiles of PD-1, PD-L1, PD-L2 in gastric cancer and their relation with mutation, immune infiltration, and survival.","volume":"2020","author":"Liu","year":"2020","journal-title":"Biomed Res Int"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"103753","DOI":"10.1016\/j.cellimm.2018.01.013","article-title":"Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone?","volume":"343","author":"Badalamenti","year":"2019","journal-title":"Cell Immunol"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"e002356","DOI":"10.1136\/jitc-2021-002356","article-title":"Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.","volume":"9","author":"Zhang","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis.","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"608422","DOI":"10.3389\/fendo.2020.608422","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas.","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R33-20260811","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R34-20260811","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease.","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"R35-20260811","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R36-20260811","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R37-20260811","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/his.13382","article-title":"Role of immune microenvironment in gastrointestinal stromal tumours.","volume":"72","author":"Blakely","year":"2018","journal-title":"Histopathology"},{"key":"R38-20260811","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.","volume":"112","author":"Abiko","year":"2015","journal-title":"Br J Cancer"},{"key":"R39-20260811","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2010.30.5425","article-title":"Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.","volume":"29","author":"Mlecnik","year":"2011","journal-title":"J Clin Oncol"},{"key":"R40-20260811","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R41-20260811","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri3173","article-title":"The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation.","volume":"12","author":"Weng","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R42-20260811","doi-asserted-by":"crossref","first-page":"101435","DOI":"10.1016\/j.smim.2020.101435","article-title":"Memory CD8+ T cell responses to cancer.","volume":"49","author":"Han","year":"2020","journal-title":"Semin Immunol"},{"key":"R43-20260811","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance.","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"R44-20260811","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"key":"R45-20260811","doi-asserted-by":"crossref","first-page":"e1075112","DOI":"10.1080\/2162402X.2015.1075112","article-title":"PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.","volume":"5","author":"Guan","year":"2015","journal-title":"Oncoimmunology"},{"key":"R46-20260811","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ccell.2021.09.007","article-title":"B cells and cancer.","volume":"39","author":"Engelhard","year":"2021","journal-title":"Cancer Cell"},{"key":"R47-20260811","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour microenvironment.","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R48-20260811","doi-asserted-by":"crossref","first-page":"6539702","DOI":"10.1155\/2021\/6539702","article-title":"Serum CD4 is associated with the infiltration of CD4+T cells in the tumor microenvironment of gastric cancer.","volume":"2021","author":"You","year":"2021","journal-title":"J Immunol Res"},{"key":"R49-20260811","first-page":"4082","article-title":"Roles of PECAM-1 in cell function and disease progression.","volume":"20","author":"Feng","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R50-20260811","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/10428194.2020.1849678","article-title":"CD31\/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.","volume":"62","author":"Vockova","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"R51-20260811","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3892\/ol.2014.2091","article-title":"Inhibition of lung tumor growth in nude mice by siRNACD31 targeting PECAM-1.","volume":"8","author":"Ouyang","year":"2014","journal-title":"Oncol Lett"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000036323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:02:15Z","timestamp":1786435335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000036323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":51,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036323","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}